Last reviewed · How we verify

Bupivacaine + nalbuphine — Competitive Intelligence Brief

Bupivacaine + nalbuphine (Bupivacaine + nalbuphine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic + mixed opioid agonist-antagonist. Area: Pain management, Anesthesia.

marketed Local anesthetic + mixed opioid agonist-antagonist Voltage-gated sodium channels (bupivacaine); kappa and mu opioid receptors (nalbuphine) Pain management, Anesthesia Small molecule Live · refreshed every 30 min

Target snapshot

Bupivacaine + nalbuphine (Bupivacaine + nalbuphine) — Alzahraa Ahmed Abbas. Bupivacaine provides local anesthesia by blocking sodium channels in nerve fibers, while nalbuphine provides opioid analgesia by acting as a mixed kappa agonist and mu antagonist.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Bupivacaine + nalbuphine TARGET Bupivacaine + nalbuphine Alzahraa Ahmed Abbas marketed Local anesthetic + mixed opioid agonist-antagonist Voltage-gated sodium channels (bupivacaine); kappa and mu opioid receptors (nalbuphine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic + mixed opioid agonist-antagonist class)

  1. Alzahraa Ahmed Abbas · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Bupivacaine + nalbuphine — Competitive Intelligence Brief. https://druglandscape.com/ci/bupivacaine-nalbuphine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: